These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

632 related items for PubMed ID: 30115475

  • 1. Induction chemotherapy with carboplatin, nab-paclitaxel and cetuximab for at least N2b nodal status or surgically unresectable squamous cell carcinoma of the head and neck.
    Weiss J, Gilbert J, Deal AM, Weissler M, Hilliard C, Chera B, Murphy B, Hackman T, Liao JJ, Grilley Olson J, Hayes DN.
    Oral Oncol; 2018 Sep; 84():46-51. PubMed ID: 30115475
    [Abstract] [Full Text] [Related]

  • 2. A multicenter phase II trial of paclitaxel, carboplatin, and cetuximab followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck.
    Enokida T, Ogawa T, Homma A, Okami K, Minami S, Nakanome A, Shimizu Y, Maki D, Ueda Y, Fujisawa T, Motegi A, Ohkoshi A, Taguchi J, Ebisumoto K, Nomura S, Okano S, Tahara M.
    Cancer Med; 2020 Mar; 9(5):1671-1682. PubMed ID: 31943834
    [Abstract] [Full Text] [Related]

  • 3. nab-Paclitaxel-based induction chemotherapy followed by cisplatin and radiation therapy for human papillomavirus-unrelated head and neck squamous-cell carcinoma.
    Johnson KCC, Ley J, Oppelt P, Lu J, Gay HA, Daly M, Jackson R, Rich J, Pipkorn P, Paniello RC, Zevallos J, Thorstad W, Adkins DR.
    Med Oncol; 2019 Oct 08; 36(11):93. PubMed ID: 31595355
    [Abstract] [Full Text] [Related]

  • 4. Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02).
    Tahara M, Kiyota N, Yokota T, Hasegawa Y, Muro K, Takahashi S, Onoe T, Homma A, Taguchi J, Suzuki M, Minato K, Yane K, Ueda S, Hara H, Saijo K, Yamanaka T.
    Ann Oncol; 2018 Apr 01; 29(4):1004-1009. PubMed ID: 29408977
    [Abstract] [Full Text] [Related]

  • 5. Phase I study of weekly nab-paclitaxel + weekly cetuximab + intensity-modulated radiation therapy (IMRT) in patients with stage III-IVB head and neck squamous cell carcinoma (HNSCC).
    Fury MG, Sherman EJ, Rao SS, Wolden S, Smith-Marrone S, Mueller B, Ng KK, Dutta PR, Gelblum DY, Lee JL, Shen R, Kurz S, Katabi N, Haque S, Lee NY, Pfister DG.
    Ann Oncol; 2014 Mar 01; 25(3):689-694. PubMed ID: 24496920
    [Abstract] [Full Text] [Related]

  • 6. Phase 1 study of nab-paclitaxel, cisplatin and 5-fluorouracil as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced squamous cell carcinoma of the oropharynx.
    Loong HH, Winquist E, Waldron J, Chen EX, Kim J, Palma D, Read N, Razak AR, Diaz-Padilla I, Chan K, Bayley A, Hossain M, Wang L, Chin S, Siu LL, Hope A.
    Eur J Cancer; 2014 Sep 01; 50(13):2263-70. PubMed ID: 24953566
    [Abstract] [Full Text] [Related]

  • 7. A Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma.
    Keam B, Lee KW, Lee SH, Kim JS, Kim JH, Wu HG, Eom KY, Kim S, Ahn SH, Chung EJ, Kwon SK, Jeong WJ, Jung YH, Kim JW, Heo DS.
    Oncologist; 2019 Jun 01; 24(6):751-e231. PubMed ID: 30796155
    [Abstract] [Full Text] [Related]

  • 8. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
    Suntharalingam M, Jaboin J, Taylor R, Wolf J, Banglore M, Van Echo D, Ord R.
    Semin Oncol; 2004 Dec 01; 31(6 Suppl 18):2-7. PubMed ID: 15726515
    [Abstract] [Full Text] [Related]

  • 9. Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma.
    Haddad RI, Massarelli E, Lee JJ, Lin HY, Hutcheson K, Lewis J, Garden AS, Blumenschein GR, William WN, Pharaon RR, Tishler RB, Glisson BS, Pickering C, Gold KA, Johnson FM, Rabinowits G, Ginsberg LE, Williams MD, Myers J, Kies MS, Papadimitrakopoulou V.
    Ann Oncol; 2019 Mar 01; 30(3):471-477. PubMed ID: 30596812
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Efficacy and feasibility of induction chemotherapy with paclitaxel, carboplatin and cetuximab for locally advanced unresectable head and neck cancer patients ineligible for combination treatment with docetaxel, cisplatin, and 5-fluorouracil.
    Shirasu H, Yokota T, Kawakami T, Hamauchi S, Onozawa Y, Ogawa H, Onoe T, Mori K, Onitsuka T.
    Int J Clin Oncol; 2020 Nov 01; 25(11):1914-1920. PubMed ID: 32648132
    [Abstract] [Full Text] [Related]

  • 15. Phase II study evaluating the addition of cetuximab to the concurrent delivery of weekly carboplatin, paclitaxel, and daily radiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck.
    Suntharalingam M, Kwok Y, Goloubeva O, Parekh A, Taylor R, Wolf J, Zimrin A, Strome S, Ord R, Cullen KJ.
    Int J Radiat Oncol Biol Phys; 2012 Apr 01; 82(5):1845-50. PubMed ID: 21601372
    [Abstract] [Full Text] [Related]

  • 16. Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck.
    Wirth LJ, Allen AM, Posner MR, Haddad RI, Li Y, Clark JR, Busse PM, Chan AW, Goguen LA, Norris CM, Annino DJ, Tishler RB.
    Ann Oncol; 2010 Feb 01; 21(2):342-347. PubMed ID: 19892746
    [Abstract] [Full Text] [Related]

  • 17. Induction TPF chemotherapy followed by CRT with fractionated administration of cisplatin in patients with unresectable locally advanced head and neck cancer.
    Okano S, Enokida T, Onoe T, Ota Y, Motegi A, Zenda S, Akimoto T, Tahara M.
    Int J Clin Oncol; 2019 Jul 01; 24(7):789-797. PubMed ID: 30796560
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a toxicity analysis.
    Birnbaum A, Dipetrillo T, Rathore R, Anderson E, Wanebo H, Puthwala Y, Joyce D, Safran H, Henderson D, Kennedy T, Ready N, Sio TT.
    Am J Clin Oncol; 2010 Apr 01; 33(2):144-7. PubMed ID: 19786848
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.